Our team of data scientists, microbiologists, computational chemists, and chemical biologists is supported by a Board of Directors with a wealth of experience in medicinal chemistry, drug discovery and development, and venture capital
Andy Haigh, PhD
President, CEO, and Board Member
Board of Directors
Andy Haigh, PhD President, CEO, and Board Member
Andy Haigh is the President and CEO of Adapsyn Bioscience. He joined the company in 2017 after being instrumental in the company’s initial financing and collaboration. He was previously the second employee at Forbius Inc., a biologic drug developer acquired by BMS in 2020. Additionally, he spent five years at Lumira Capital, a leading Canadian venture capital firm, where he executed both equity and debt transactions in public and private companies developing novel therapeutics. He currently serves on the Board of Directors at BIOTECanada, Canada’s biotechnology industry association, and is the chair of the organization’s Emerging Company Advisory Board. Andy holds a PhD in Biology from Dalhousie University and an MBA from the Ivey Business School at Western University.
Christopher O’Donnell, PhD Board Member
Christopher O’Donnell, PHD is Executive Director, WRD and Principal at Pfizer Ventures. Chris is responsible for identifying, evaluating, making and managing equity investments aligned with the future directions of Pfizer. He currently has responsibility for Pfizer’s investments in Adapsyn, BioAtla, Kymera, Morphic, Petra, Storm Therapeutics, and Strata Oncology. Chris brings 19 years of scientific leadership, a strong track record of delivering clinical candidates across multiple disease areas and modalities, and proven ability to build and lead highly engaged teams. He most recently built and led the Applied Synthesis Technologies group within R&D to help accelerate the delivery of Pfizer’s small molecule portfolio. Prior to that, Chris built and led Pfizer’s Antibody Drug Conjugate Oncology Medicinal Chemistry group which delivered new linker, payload and conjugation methods resulting in over 7 conjugates entering clinical development. Chris started his career in the Neuroscience Medicinal Chemistry group where he invented and helped deliver numerous clinical candidates. Chris received his BS in Chemistry from the University of Illinois-Urbana/Champaign and his PhD in Chemistry from the University of Wisconsin-Madison.
Kelly Holman Board Member
Mr. Holman is co-Founder and Managing Director of Genesys Capital and has extensive commercial and technical experience in the biotechnology industry. Since co-founding Genesys Capital in 2000, Mr. Holman has been actively involved in raising over $300 million of venture capital and has been instrumental in deploying over $160 million across 30 investments. He currently serves on the Board of Directors of Functional Neuromodulation Ltd. and Adapsyn Bioscience Inc. From 2012-2015, he was a board observer with Invitae (NYSE: NVTA), and from 2001 to 2013, he served on the board of Epocal (acquired by Alere, NYSE: ALR). Mr. Holman also sits on the Board of Directors of the Ontario Biotechnology Innovation Organization (OBIO). Prior to co-founding Genesys Capital, Mr. Holman was a Senior Investment Manager with MDS Capital Corporation. Previously, Mr. Holman worked in the laboratory of Dr. Peter St George-Hyslop at the University of Toronto where he was a key member of the international research team that discovered several genes responsible for Alzheimer’s disease. Mr. Holman holds a Bachelor of Science (Honours) in Biochemistry and an MBA, both from Queen’s.
Nathan Magarvey, PhD Board Member
Dr. Nathan Magarvey is an Associate Professor and Canada Research Chair in Natural Products and Chemical Biology in the Department of Biochemistry and Biomedical Sciences & Chemistry and Chemical Biology at McMaster University and the Founder of Adapsyn Bioscience. He joined McMaster from Harvard Medical School and previously spent time in the pharmaceutical industry working for Wyeth Research, where he was directly involved in the discovery of new antibiotic and therapeutic microbial natural product small molecules. Dr. Magarvey’s research focuses on disrupting how the discovery of microbial metabolites is done- and in particular how to leverage the ability to connect Genomes to Natural Products, and his research has advanced the discovery of new microbial small molecules. His work leads to research intersecting the interfaces of medicine, biology, chemistry and computer science.
Lloyd Mackenzie Board Member
Mr. Mackenzie joined Aquinox in May 2008 and was promoted to Vice President in May of 2013. Responsible for the company’s research and development activities, Mr. Mackenzie has over 22 years of experience in the biopharmaceutical industry with expertise in medicinal chemistry, biochemistry, and CMC. He is the author of 15 scientific publications and is an inventor on four patents. Prior to joining Aquinox, Mr. Mackenzie was a Research Scientist for Pharmaceutical Development at QLT Inc. Prior to that, Mr. Mackenzie was a Research Scientist at Inflazyme Pharmaceuticals Inc.